| 摘要 |
This invention concerns an immunoassay for quantitative determination of the amount of the complex (PSA-A<HIL><PDAT>2</SB><PDAT>M) between prostate specific antigen (PSA) and alpha<HIL><PDAT>2</SB><PDAT>-macroglobulin (A<HIL><PDAT>2</SB><PDAT>M) in a sample. The assay comprises the steps of removing immunoreactive PSA from the sample, treating the PSA-A<HIL><PDAT>2</SB><PDAT>M complex in the remaining supernatant so as to make the PSA thereof immunoreactive, determining the immunoreactive PSA derived from the PSA-A<HIL><PDAT>2</SB><PDAT>M complex by exposing it to an antibody which binds immunoreactive PSA, and detecting the PSA. The invention also concerns a method for differentiating patients with cancer of the prostate (PCa) from patients with benign prostatic hyperplasia (BPH) or healthy male subjects without PCa, wherein the individual's body fluid concentration of PSA has been determined as free PSA and as total PSA. The method is characterized in that PSA complexed with A<HIL><PDAT>2</SB><PDAT>M (PSA-A<HIL><PDAT>2</SB><PDAT>M) in the individual's serum sample has been determined, and that the ration between PSA-A<HIL><PDAT>2</SB><PDAT>M and other forms of PSA is calculated, or that the diagnostic value is calculated by logistic regression, neural networks, fussy logic or similar mathematical and statistical methods using PSA-A<HIL><PDAT>2</SB><PDAT>M and other forms of PSA, such as total PSA, free PSA and PSA-ACT as input variables.</PTEXT>
|
